Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PAM | P19021 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28003655 | 0.75 | ALDH1A1 (0.46) | ALDH1A1ALDH3A1RCE1MAPTPAM | |
| SCHEMBL28003654 | 0.75 | ALDH1A1 (0.46) | ALDH1A1ALDH3A1RCE1MAPTPAM | |
| SCHEMBL4101771 | 0.70 | DBH (0.62) | ALDH1A1HPGDTSHRPOLBCYP3A4 | |
| SCHEMBL11632469 | 0.70 | ALDH1A1 (0.45) | ALDH1A1ALDH3A1RCE1MAPTPAM | |
| SCHEMBL175260 | 0.70 | — | — | |
| SCHEMBL12668379 | 0.70 | ALDH1A1 (0.51) | ALDH1A1ALDH3A1RCE1MAPTPAM | |
| SCHEMBL11011183 | 0.70 | ALDH1A1 (0.51) | ALDH1A1ALDH3A1RCE1MAPTPAM | |
| SCHEMBL23847348 | 0.66 | ALDH1A1 (0.69) | ALDH1A1ALDH3A1RCE1MAPTPAM | |
| SCHEMBL10421306 | 0.66 | ALDH1A1 (0.69) | ALDH1A1ALDH3A1RCE1MAPTPAM | |
| SCHEMBL10988258 | 0.65 | OPRD1 (0.42) | ALDH1A1ALDH3A1RCE1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102725305-B | Melanocortin-1 receptor-specific cyclic peptides | 帕拉丁科技公司 | 2016-08-24 | — | — | CN | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-7674811-B2 | 5-lipoxygenase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-09 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-24 | — | — | US | disclosed |
| EP-1834953-A1 | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors | Ranbaxy Laboratories Limited (IN) | 2007-09-19 | — | — | EP | disclosed |
| US-6656959-B1 | PDE IV inhibiting pyridine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-02 | — | — | US | disclosed |
| EP-1068194-B1 | PDE IV INHIBITING PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-11-05 | — | — | EP | disclosed |
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2002-06-06 | — | — | US | disclosed |
| EP-0819122-B1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | ALDH1A1 4063/4885ALDH3A1 2470/4885RCE1 896/4885 |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | HRH2, CBR1, HRH1 | ALDH1A1 351/4885ALDH3A1 211/4885RCE1 1440/4885 |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | ALDH1A1 4063/4885ALDH3A1 2470/4885RCE1 896/4885 |
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALDH1A1 210/4885ALDH3A1 357/4885RCE1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.